Cargando…

Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India

BACKGROUND: The COVID-19 vaccination program was introduced in India on 16 January 2021. The Government-issued fact sheet was the only source of information regarding Adverse Events Following Immunizations (AEFIs) for these vaccines. The objective of this study was to assess the AEFIs reported follo...

Descripción completa

Detalles Bibliográficos
Autores principales: Basavaraja, Chetak Kadabasal, Sebastian, Juny, Ravi, Mandyam Dhati, John, Sheba Baby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611289/
https://www.ncbi.nlm.nih.gov/pubmed/34841193
http://dx.doi.org/10.1177/25151355211055833
_version_ 1784603267302424576
author Basavaraja, Chetak Kadabasal
Sebastian, Juny
Ravi, Mandyam Dhati
John, Sheba Baby
author_facet Basavaraja, Chetak Kadabasal
Sebastian, Juny
Ravi, Mandyam Dhati
John, Sheba Baby
author_sort Basavaraja, Chetak Kadabasal
collection PubMed
description BACKGROUND: The COVID-19 vaccination program was introduced in India on 16 January 2021. The Government-issued fact sheet was the only source of information regarding Adverse Events Following Immunizations (AEFIs) for these vaccines. The objective of this study was to assess the AEFIs reported following COVID-19 vaccination in a tertiary care teaching hospital. MATERIALS AND METHODS: The spontaneous reporting method was used for data collection for a period of 3 months. A data collection form was designed to collect the data from the study population who reported adverse events. Collected data were analyzed and categorized by severity and seriousness. The causality assessment team performed causality assessment of the AEFIs using the World Health Organization’s causality assessment algorithm. RESULTS: A total of 11,656 doses of COVID-19 vaccine were administered at the study site during the study period, of which 9292 doses were COVISHIELD™ and 2364 doses were COVAXIN™. In all, 445 AEFIs were reported from 269 subjects with an incidence rate of 3.48%. The majority of the subjects with AEFIs belonged to the age group of 18–45 years. Out of the total 445 AEFIs, 418 AEFIs were expected as per the fact sheets, 409 with COVISHIELD™ and 9 with COVAXIN™. Most of the AEFIs [62.02% (n = 276)] were observed at the system organ class of ‘General disorders and administration site conditions’. After the causality assessment, out of 433 AEFIs to COVISHIELD(TM) vaccine, 94.22% (n = 408) of events were categorized to have ‘consistent causal association with immunization’. Out of 12 adverse events following COVAXIN™, 8 (66.66%) events were categorized as ‘consistent causal association with immunization’. All of them recovered from their adverse events without any sequelae. CONCLUSION: Spontaneous reporting is one of the cheapest methods that can be used for the reporting of AEFI. This method helps health care professionals to identify rare events and potential signals.
format Online
Article
Text
id pubmed-8611289
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-86112892021-11-25 Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India Basavaraja, Chetak Kadabasal Sebastian, Juny Ravi, Mandyam Dhati John, Sheba Baby Ther Adv Vaccines Immunother Original Research BACKGROUND: The COVID-19 vaccination program was introduced in India on 16 January 2021. The Government-issued fact sheet was the only source of information regarding Adverse Events Following Immunizations (AEFIs) for these vaccines. The objective of this study was to assess the AEFIs reported following COVID-19 vaccination in a tertiary care teaching hospital. MATERIALS AND METHODS: The spontaneous reporting method was used for data collection for a period of 3 months. A data collection form was designed to collect the data from the study population who reported adverse events. Collected data were analyzed and categorized by severity and seriousness. The causality assessment team performed causality assessment of the AEFIs using the World Health Organization’s causality assessment algorithm. RESULTS: A total of 11,656 doses of COVID-19 vaccine were administered at the study site during the study period, of which 9292 doses were COVISHIELD™ and 2364 doses were COVAXIN™. In all, 445 AEFIs were reported from 269 subjects with an incidence rate of 3.48%. The majority of the subjects with AEFIs belonged to the age group of 18–45 years. Out of the total 445 AEFIs, 418 AEFIs were expected as per the fact sheets, 409 with COVISHIELD™ and 9 with COVAXIN™. Most of the AEFIs [62.02% (n = 276)] were observed at the system organ class of ‘General disorders and administration site conditions’. After the causality assessment, out of 433 AEFIs to COVISHIELD(TM) vaccine, 94.22% (n = 408) of events were categorized to have ‘consistent causal association with immunization’. Out of 12 adverse events following COVAXIN™, 8 (66.66%) events were categorized as ‘consistent causal association with immunization’. All of them recovered from their adverse events without any sequelae. CONCLUSION: Spontaneous reporting is one of the cheapest methods that can be used for the reporting of AEFI. This method helps health care professionals to identify rare events and potential signals. SAGE Publications 2021-11-22 /pmc/articles/PMC8611289/ /pubmed/34841193 http://dx.doi.org/10.1177/25151355211055833 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Basavaraja, Chetak Kadabasal
Sebastian, Juny
Ravi, Mandyam Dhati
John, Sheba Baby
Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India
title Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India
title_full Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India
title_fullStr Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India
title_full_unstemmed Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India
title_short Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India
title_sort adverse events following covid-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in south india
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611289/
https://www.ncbi.nlm.nih.gov/pubmed/34841193
http://dx.doi.org/10.1177/25151355211055833
work_keys_str_mv AT basavarajachetakkadabasal adverseeventsfollowingcovid19vaccinationfirst90daysofexperiencefromatertiarycareteachinghospitalinsouthindia
AT sebastianjuny adverseeventsfollowingcovid19vaccinationfirst90daysofexperiencefromatertiarycareteachinghospitalinsouthindia
AT ravimandyamdhati adverseeventsfollowingcovid19vaccinationfirst90daysofexperiencefromatertiarycareteachinghospitalinsouthindia
AT johnshebababy adverseeventsfollowingcovid19vaccinationfirst90daysofexperiencefromatertiarycareteachinghospitalinsouthindia